SG11201609208UA - Ceritinib formulation - Google Patents

Ceritinib formulation

Info

Publication number
SG11201609208UA
SG11201609208UA SG11201609208UA SG11201609208UA SG11201609208UA SG 11201609208U A SG11201609208U A SG 11201609208UA SG 11201609208U A SG11201609208U A SG 11201609208UA SG 11201609208U A SG11201609208U A SG 11201609208UA SG 11201609208U A SG11201609208U A SG 11201609208UA
Authority
SG
Singapore
Prior art keywords
ceritinib
formulation
ceritinib formulation
Prior art date
Application number
SG11201609208UA
Inventor
Sebastien Breulles
Simon Ensslin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53298568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201609208U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG11201609208UA publication Critical patent/SG11201609208UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
SG11201609208UA 2014-05-29 2015-05-27 Ceritinib formulation SG11201609208UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462004359P 2014-05-29 2014-05-29
PCT/IB2015/053966 WO2015181739A1 (en) 2014-05-29 2015-05-27 Ceritinib formulation

Publications (1)

Publication Number Publication Date
SG11201609208UA true SG11201609208UA (en) 2016-12-29

Family

ID=53298568

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201609208UA SG11201609208UA (en) 2014-05-29 2015-05-27 Ceritinib formulation

Country Status (27)

Country Link
US (4) US20170112834A1 (en)
EP (1) EP3148513B1 (en)
JP (3) JP6679578B2 (en)
KR (1) KR20170008239A (en)
CN (1) CN106456640B (en)
AR (1) AR100625A1 (en)
AU (3) AU2015265470A1 (en)
BR (1) BR112016027580A8 (en)
CA (1) CA2948291A1 (en)
CL (1) CL2016003047A1 (en)
DK (1) DK3148513T3 (en)
EA (1) EA036922B1 (en)
EC (1) ECSP16096826A (en)
ES (1) ES2792574T3 (en)
HU (1) HUE048950T2 (en)
IL (1) IL248835B (en)
MX (1) MX2016015736A (en)
PE (1) PE20170313A1 (en)
PH (1) PH12016502272A1 (en)
PL (1) PL3148513T3 (en)
PT (1) PT3148513T (en)
SG (1) SG11201609208UA (en)
SI (1) SI3148513T1 (en)
TN (1) TN2016000484A1 (en)
TW (1) TWI721946B (en)
UY (1) UY36140A (en)
WO (1) WO2015181739A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106176752B (en) * 2015-05-07 2020-06-23 石药集团中奇制药技术（石家庄）有限公司 Ceritinib pharmaceutical composition
CN109381440A (en) * 2018-11-15 2019-02-26 威海贯标信息科技有限公司 A kind of Ai Le replaces nylon 6 combination
CN113244236B (en) * 2021-06-01 2023-02-03 上海市第一人民医院 Application of ceritinib in preparation of medicine for treating thyroid-associated ophthalmopathy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632778A (en) * 1970-06-10 1972-01-04 Hoffmann La Roche Tablets containing l-dopa
AR059739A1 (en) * 2006-03-06 2008-04-23 Wyeth Corp FORMULATIONS AND PROCESSES FOR TABLETS
US20090239920A1 (en) * 2006-11-21 2009-09-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175901A1 (en) * 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
MX2009006081A (en) * 2006-12-08 2009-06-17 Irmc Llc Compounds and compositions as protein kinase inhibitors.
SI2091918T1 (en) * 2006-12-08 2015-01-30 Irm Llc Compounds and compositions as protein kinase inhibitors
EP2090297A1 (en) 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
CN102143692A (en) * 2008-09-04 2011-08-03 卡吉尔公司 Tabletting of ervthritol
JO3635B1 (en) * 2009-05-18 2020-08-27 Millennium Pharm Inc Solid pharmaceutical compositions and processes for their production
CN102480998B (en) * 2009-08-18 2016-05-25 卡吉尔公司 The compressing tablet of erythrite and isomalt
TWI564034B (en) 2010-05-11 2017-01-01 田邊三菱製藥股份有限公司 Tablets containing a 1-(β-d-glucopyranosyl)-3-(phenylthienylmethyl)benzene compound
KR20130138774A (en) * 2010-09-07 2013-12-19 카아길, 인코포레이팃드 Solidified sugar alcohol mixture

Also Published As

Publication number Publication date
AU2018203007B2 (en) 2019-07-18
TW201613580A (en) 2016-04-16
AR100625A1 (en) 2016-10-19
WO2015181739A1 (en) 2015-12-03
US20200009141A1 (en) 2020-01-09
IL248835A0 (en) 2017-01-31
UY36140A (en) 2016-01-08
CN106456640A (en) 2017-02-22
US20190022095A1 (en) 2019-01-24
HUE048950T2 (en) 2020-09-28
MX2016015736A (en) 2017-03-16
KR20170008239A (en) 2017-01-23
ECSP16096826A (en) 2018-04-30
CA2948291A1 (en) 2015-12-03
US20170112834A1 (en) 2017-04-27
EP3148513B1 (en) 2020-02-26
JP6679578B2 (en) 2020-04-15
AU2018203007A1 (en) 2018-05-17
JP2020114834A (en) 2020-07-30
AU2019232937B2 (en) 2020-10-15
JP2022078236A (en) 2022-05-24
BR112016027580A2 (en) 2017-08-15
PE20170313A1 (en) 2017-04-18
JP7084955B2 (en) 2022-06-15
ES2792574T3 (en) 2020-11-11
TWI721946B (en) 2021-03-21
AU2015265470A1 (en) 2016-11-24
CN106456640B (en) 2021-05-14
PH12016502272A1 (en) 2017-02-06
TN2016000484A1 (en) 2018-04-04
DK3148513T3 (en) 2020-05-25
EA201692310A1 (en) 2017-04-28
BR112016027580A8 (en) 2021-06-29
CL2016003047A1 (en) 2017-04-07
EP3148513A1 (en) 2017-04-05
EA036922B1 (en) 2021-01-15
IL248835B (en) 2020-05-31
US20210154194A1 (en) 2021-05-27
US11000523B2 (en) 2021-05-11
SI3148513T1 (en) 2020-07-31
PL3148513T3 (en) 2020-08-24
PT3148513T (en) 2020-05-27
JP2017520619A (en) 2017-07-27
AU2019232937A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
GB201407934D0 (en) Formulation
GB201513010D0 (en) Novel formulation
IL250343A0 (en) Factor viii formulation
GB201514758D0 (en) Formulation
GB201419261D0 (en) Formulations
GB201419091D0 (en) Formulations
GB201416727D0 (en) Use
GB201416716D0 (en) Use
IL248835B (en) Ceritinib formulation
RS62057B1 (en) Maropitant formulation
GB201407384D0 (en) Formulation
IL251362A0 (en) Formulation
GB201521771D0 (en) Formulation
GB201511301D0 (en) Formulation
GB201511255D0 (en) Formulation
GB201509891D0 (en) Formulation
GB201402448D0 (en) Novel formulation
GB201416536D0 (en) Formulation
GB201416274D0 (en) Formulation
GB201514014D0 (en) Formulation
GB201412754D0 (en) Formulation
GB201404773D0 (en) Formulation
GB201504662D0 (en) Formulation
GB201508527D0 (en) Novel formulation
GB201421960D0 (en) Use